Publications

November 14, 2022

Targeting platelet GPVI with glenzocimab : a novel mechanism for inhibition – Blood Advances

Publications

November 14, 2022

Cibler le GPVI plaquettaire avec le glenzocimab : un nouveau mécanisme d'inhibition. – Blood Advances (EN)

Publications

November 14, 2022

Targeting platelet GPVI with glenzocimab : a novel mechanism for inhibition – Blood Advances

Publications

November 14, 2022

Cibler le GPVI plaquettaire avec le glenzocimab : un nouveau mécanisme d'inhibition. – Blood Advances (EN)

Publications

November 14, 2022

Targeting platelet GPVI with glenzocimab : a novel mechanism for inhibition – Blood Advances

Publications

November 14, 2022

Cibler le GPVI plaquettaire avec le glenzocimab : un nouveau mécanisme d'inhibition. – Blood Advances (EN)

Publications

1er juillet 2021

Glenzocimab does not impact glycoprotein VI-dependent inflammatory haemostasis

Publications

1er juillet 2021

Glenzocimab does not impact glycoprotein VI-dependent inflammatory haemostasis

Publications

1er juillet 2021

Glenzocimab does not impact glycoprotein VI-dependent inflammatory haemostasis

Publications

1er juillet 2021

Glenzocimab does not impact glycoprotein VI-dependent inflammatory haemostasis

Publications

1er juillet 2021

Glenzocimab does not impact glycoprotein VI-dependent inflammatory haemostasis

Publications

1er juillet 2021

Glenzocimab does not impact glycoprotein VI-dependent inflammatory haemostasis

Publications

1er septembre 2020

Pharmacological Blockade of Glycoprotein VI Promotes Thrombus Disaggregation in the Absence of Thrombin

Publications

1er septembre 2020

Pharmacological Blockade of Glycoprotein VI Promotes Thrombus Disaggregation in the Absence of Thrombin

Publications

1er septembre 2020

Pharmacological Blockade of Glycoprotein VI Promotes Thrombus Disaggregation in the Absence of Thrombin

Publications

1er septembre 2020

Pharmacological Blockade of Glycoprotein VI Promotes Thrombus Disaggregation in the Absence of Thrombin

Publications

1er septembre 2020

Pharmacological Blockade of Glycoprotein VI Promotes Thrombus Disaggregation in the Absence of Thrombin

Publications

1er septembre 2020

Pharmacological Blockade of Glycoprotein VI Promotes Thrombus Disaggregation in the Absence of Thrombin

Publications

9 juin 2020

Population Pharmacokinetic/ Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen-Induced Platelet Aggregation

Publications

9 juin 2020

Population Pharmacokinetic/ Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen-Induced Platelet Aggregation

Publications

9 juin 2020

Population Pharmacokinetic/ Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen-Induced Platelet Aggregation

Publications

9 juin 2020

Population Pharmacokinetic/ Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen-Induced Platelet Aggregation

Publications

9 juin 2020

Population Pharmacokinetic/ Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen-Induced Platelet Aggregation

Publications

9 juin 2020

Population Pharmacokinetic/ Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen-Induced Platelet Aggregation

Publications

29 mai 2019

Acute ischemic stroke thrombi have an outer shell that impairs fibrinolysis

Publications

29 mai 2019

Acute ischemic stroke thrombi have an outer shell that impairs fibrinolysis

Publications

29 mai 2019

Acute ischemic stroke thrombi have an outer shell that impairs fibrinolysis

Publications

29 mai 2019

Acute ischemic stroke thrombi have an outer shell that impairs fibrinolysis

Publications

29 mai 2019

Acute ischemic stroke thrombi have an outer shell that impairs fibrinolysis

Publications

29 mai 2019

Acute ischemic stroke thrombi have an outer shell that impairs fibrinolysis

Publications

25 avril 2019

Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab

Publications

25 avril 2019

Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab

Publications

25 avril 2019

Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab

Publications

25 avril 2019

Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab

Publications

25 avril 2019

Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab

Publications

25 avril 2019

Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab

Publications

26 avril 2018

Quality and cost assessment of a recombinant antibody fragment produced from mammalian, yeast and prokaryotic host cells: A case study prior to pharmaceutical development

Publications

26 avril 2018

Quality and cost assessment of a recombinant antibody fragment produced from mammalian, yeast and prokaryotic host cells: A case study prior to pharmaceutical development

Publications

26 avril 2018

Quality and cost assessment of a recombinant antibody fragment produced from mammalian, yeast and prokaryotic host cells: A case study prior to pharmaceutical development

Publications

26 avril 2018

Quality and cost assessment of a recombinant antibody fragment produced from mammalian, yeast and prokaryotic host cells: A case study prior to pharmaceutical development

Publications

26 avril 2018

Quality and cost assessment of a recombinant antibody fragment produced from mammalian, yeast and prokaryotic host cells: A case study prior to pharmaceutical development

Publications

26 avril 2018

Quality and cost assessment of a recombinant antibody fragment produced from mammalian, yeast and prokaryotic host cells: A case study prior to pharmaceutical development

Publications

22 février 2018

Immobilized fibrinogen activates human platelets through glycoprotein VI

Publications

22 février 2018

Immobilized fibrinogen activates human platelets through glycoprotein VI

Publications

22 février 2018

Immobilized fibrinogen activates human platelets through glycoprotein VI

Publications

22 février 2018

Immobilized fibrinogen activates human platelets through glycoprotein VI

Publications

22 février 2018

Immobilized fibrinogen activates human platelets through glycoprotein VI

Publications

22 février 2018

Immobilized fibrinogen activates human platelets through glycoprotein VI

Publications

9 juin 2017

Design, development and characterization of ACT017, a humanized Fab that blocks platelet’s glycoprotein VI function without causing bleeding risks

Publications

9 juin 2017

Design, development and characterization of ACT017, a humanized Fab that blocks platelet’s glycoprotein VI function without causing bleeding risks

Publications

9 juin 2017

Design, development and characterization of ACT017, a humanized Fab that blocks platelet’s glycoprotein VI function without causing bleeding risks

Publications

9 juin 2017

Design, development and characterization of ACT017, a humanized Fab that blocks platelet’s glycoprotein VI function without causing bleeding risks

Publications

9 juin 2017

Design, development and characterization of ACT017, a humanized Fab that blocks platelet’s glycoprotein VI function without causing bleeding risks

Publications

9 juin 2017

Design, development and characterization of ACT017, a humanized Fab that blocks platelet’s glycoprotein VI function without causing bleeding risks

Publications

1er mai 2016

International Journal of Stroke: Beyond antiplatelets: The role of glycoprotein VI in ischemic stroke

Publications

1er mai 2016

International Journal of Stroke: Beyond antiplatelets: The role of glycoprotein VI in ischemic stroke

Publications

1er mai 2016

International Journal of Stroke: Beyond antiplatelets: The role of glycoprotein VI in ischemic stroke

Publications

1er mai 2016

International Journal of Stroke: Beyond antiplatelets: The role of glycoprotein VI in ischemic stroke

Publications

1er mai 2016

International Journal of Stroke: Beyond antiplatelets: The role of glycoprotein VI in ischemic stroke

Publications

1er mai 2016

Publications

Targeting platelet GPVI with glenzocimab : a novel mechanism for inhibition – Blood Advances

Cibler le GPVI plaquettaire avec le glenzocimab : un nouveau mécanisme d'inhibition. – Blood Advances (EN)

Targeting platelet GPVI with glenzocimab : a novel mechanism for inhibition – Blood Advances

Cibler le GPVI plaquettaire avec le glenzocimab : un nouveau mécanisme d'inhibition. – Blood Advances (EN)

Targeting platelet GPVI with glenzocimab : a novel mechanism for inhibition – Blood Advances

Cibler le GPVI plaquettaire avec le glenzocimab : un nouveau mécanisme d'inhibition. – Blood Advances (EN)

Glenzocimab does not impact glycoprotein VI-dependent inflammatory haemostasis

Glenzocimab does not impact glycoprotein VI-dependent inflammatory haemostasis

Glenzocimab does not impact glycoprotein VI-dependent inflammatory haemostasis

Glenzocimab does not impact glycoprotein VI-dependent inflammatory haemostasis

Glenzocimab does not impact glycoprotein VI-dependent inflammatory haemostasis

Glenzocimab does not impact glycoprotein VI-dependent inflammatory haemostasis

Pharmacological Blockade of Glycoprotein VI Promotes Thrombus Disaggregation in the Absence of Thrombin

Pharmacological Blockade of Glycoprotein VI Promotes Thrombus Disaggregation in the Absence of Thrombin

Pharmacological Blockade of Glycoprotein VI Promotes Thrombus Disaggregation in the Absence of Thrombin

Pharmacological Blockade of Glycoprotein VI Promotes Thrombus Disaggregation in the Absence of Thrombin

Pharmacological Blockade of Glycoprotein VI Promotes Thrombus Disaggregation in the Absence of Thrombin

Pharmacological Blockade of Glycoprotein VI Promotes Thrombus Disaggregation in the Absence of Thrombin

Population Pharmacokinetic/ Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen-Induced Platelet Aggregation

Population Pharmacokinetic/ Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen-Induced Platelet Aggregation

Population Pharmacokinetic/ Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen-Induced Platelet Aggregation

Population Pharmacokinetic/ Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen-Induced Platelet Aggregation

Population Pharmacokinetic/ Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen-Induced Platelet Aggregation

Population Pharmacokinetic/ Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen-Induced Platelet Aggregation

Acute ischemic stroke thrombi have an outer shell that impairs fibrinolysis

Acute ischemic stroke thrombi have an outer shell that impairs fibrinolysis

Acute ischemic stroke thrombi have an outer shell that impairs fibrinolysis

Acute ischemic stroke thrombi have an outer shell that impairs fibrinolysis

Acute ischemic stroke thrombi have an outer shell that impairs fibrinolysis

Acute ischemic stroke thrombi have an outer shell that impairs fibrinolysis

Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab

Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab

Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab

Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab

Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab

Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab

Quality and cost assessment of a recombinant antibody fragment produced from mammalian, yeast and prokaryotic host cells: A case study prior to pharmaceutical development

Quality and cost assessment of a recombinant antibody fragment produced from mammalian, yeast and prokaryotic host cells: A case study prior to pharmaceutical development

Quality and cost assessment of a recombinant antibody fragment produced from mammalian, yeast and prokaryotic host cells: A case study prior to pharmaceutical development

Quality and cost assessment of a recombinant antibody fragment produced from mammalian, yeast and prokaryotic host cells: A case study prior to pharmaceutical development

Quality and cost assessment of a recombinant antibody fragment produced from mammalian, yeast and prokaryotic host cells: A case study prior to pharmaceutical development

Quality and cost assessment of a recombinant antibody fragment produced from mammalian, yeast and prokaryotic host cells: A case study prior to pharmaceutical development

Immobilized fibrinogen activates human platelets through glycoprotein VI

Immobilized fibrinogen activates human platelets through glycoprotein VI

Immobilized fibrinogen activates human platelets through glycoprotein VI

Immobilized fibrinogen activates human platelets through glycoprotein VI

Immobilized fibrinogen activates human platelets through glycoprotein VI

Immobilized fibrinogen activates human platelets through glycoprotein VI

Design, development and characterization of ACT017, a humanized Fab that blocks platelet’s glycoprotein VI function without causing bleeding risks

Design, development and characterization of ACT017, a humanized Fab that blocks platelet’s glycoprotein VI function without causing bleeding risks

Design, development and characterization of ACT017, a humanized Fab that blocks platelet’s glycoprotein VI function without causing bleeding risks

Design, development and characterization of ACT017, a humanized Fab that blocks platelet’s glycoprotein VI function without causing bleeding risks

Design, development and characterization of ACT017, a humanized Fab that blocks platelet’s glycoprotein VI function without causing bleeding risks

Design, development and characterization of ACT017, a humanized Fab that blocks platelet’s glycoprotein VI function without causing bleeding risks

International Journal of Stroke: Beyond antiplatelets: The role of glycoprotein VI in ischemic stroke

International Journal of Stroke: Beyond antiplatelets: The role of glycoprotein VI in ischemic stroke

International Journal of Stroke: Beyond antiplatelets: The role of glycoprotein VI in ischemic stroke

International Journal of Stroke: Beyond antiplatelets: The role of glycoprotein VI in ischemic stroke

International Journal of Stroke: Beyond antiplatelets: The role of glycoprotein VI in ischemic stroke

International Journal of Stroke: Beyond antiplatelets: The role of glycoprotein VI in ischemic stroke

S'abonner à l'alerte e-mail

Navigation

Nous contacter